Your browser is no longer supported. Please, upgrade your browser.
Settings
INCY [NASD]
Incyte Corporation
IndexS&P 500 P/E35.92 EPS (ttm)2.17 Insider Own0.70% Shs Outstand219.80M Perf Week-1.43%
Market Cap17.01B Forward P/E17.56 EPS next Y4.44 Insider Trans-2.59% Shs Float216.71M Perf Month-8.88%
Income478.50M PEG1.72 EPS next Q0.74 Inst Own94.30% Short Float2.71% Perf Quarter-8.10%
Sales2.70B P/S6.29 EPS this Y-166.00% Inst Trans-0.14% Short Ratio4.74 Perf Half Y-16.12%
Book/sh12.41 P/B6.29 EPS next Y48.36% ROA13.90% Target Price105.93 Perf Year-22.46%
Cash/sh9.00 P/C8.67 EPS next 5Y20.89% ROE19.00% 52W Range75.52 - 102.61 Perf YTD-10.31%
Dividend- P/FCF29.91 EPS past 5Y33.32% ROI-12.40% 52W High-23.97% Beta0.77
Dividend %- Quick Ratio3.90 Sales past 5Y28.80% Gross Margin95.90% 52W Low3.30% ATR1.75
Employees1773 Current Ratio3.90 Sales Q/Q6.40% Oper. Margin18.50% RSI (14)39.18 Volatility1.99% 1.96%
OptionableYes Debt/Eq0.01 EPS Q/Q107.30% Profit Margin17.70% Rel Volume0.98 Prev Close76.34
ShortableYes LT Debt/Eq0.01 EarningsAug 03 BMO Payout0.00% Avg Volume1.24M Price78.01
Recom2.20 SMA20-3.26% SMA50-5.49% SMA200-7.66% Volume1,211,567 Change2.19%
Jul-20-21Upgrade The Benchmark Company Hold → Buy $89
Feb-10-21Downgrade SVB Leerink Mkt Perform → Underperform $70
Jan-07-21Initiated Truist Buy $120
Jan-04-21Upgrade Guggenheim Neutral → Buy
Jun-16-20Initiated The Benchmark Company Hold
May-06-20Downgrade JP Morgan Overweight → Neutral $89 → $99
Apr-29-20Downgrade Morgan Stanley Overweight → Equal-Weight $94
Apr-01-20Upgrade Morgan Stanley Equal-Weight → Overweight $83 → $90
Mar-24-20Resumed William Blair Outperform
Mar-13-20Upgrade BofA/Merrill Neutral → Buy $83
Feb-04-20Resumed BofA/Merrill Neutral $82
Jan-03-20Reiterated BMO Capital Markets Market Perform $85 → $74
Jan-03-20Downgrade Mizuho Buy → Neutral $98 → $79
Jan-02-20Downgrade Guggenheim Buy → Neutral
Oct-03-19Initiated Mizuho Buy $95
Sep-12-19Initiated BMO Capital Markets Market Perform
Sep-05-19Upgrade Oppenheimer Perform → Outperform $100
Sep-05-19Upgrade JMP Securities Mkt Perform → Mkt Outperform $107
Sep-05-19Resumed Morgan Stanley Equal-Weight $82 → $87
May-21-19Initiated Credit Suisse Neutral $75
Jul-28-21 01:51PM  
09:59AM  
Jul-27-21 03:03PM  
Jul-23-21 04:30PM  
Jul-22-21 11:40AM  
Jul-19-21 11:16AM  
10:31AM  
Jul-16-21 01:57PM  
Jul-15-21 08:00AM  
07:56AM  
07:12AM  
Jul-14-21 05:00PM  
Jul-09-21 09:47AM  
Jul-06-21 12:43AM  
Jun-28-21 01:18PM  
11:40AM  
Jun-25-21 07:42AM  
Jun-24-21 03:30PM  
Jun-20-21 05:11AM  
Jun-14-21 10:34AM  
Jun-12-21 05:01PM  
Jun-11-21 11:40AM  
10:53AM  
07:30AM  
Jun-09-21 04:00PM  
03:53PM  
Jun-08-21 07:30AM  
Jun-04-21 02:00PM  
01:45PM  
Jun-03-21 11:31AM  
Jun-02-21 12:06PM  
Jun-01-21 07:30PM  
May-20-21 08:00AM  
06:00AM  
May-19-21 05:14PM  
May-18-21 05:07PM  
May-17-21 12:36PM  
07:30AM  
May-12-21 04:18PM  
03:47AM  
May-11-21 04:01PM  
May-04-21 01:47PM  
12:30PM  
08:25AM  
07:00AM  
06:15AM  
May-03-21 08:00AM  
07:54AM  
Apr-27-21 08:00AM  
Apr-26-21 11:41AM  
Apr-23-21 01:20PM  
10:01AM  
10:00AM  
10:00AM  
Apr-21-21 02:54PM  
12:23PM  
Apr-20-21 09:46AM  
08:00AM  
06:45AM  
Apr-19-21 04:01PM  
10:24AM  
Apr-13-21 08:00AM  
Apr-09-21 09:55AM  
Apr-08-21 07:41AM  
07:01AM  
06:45AM  
Apr-07-21 05:26PM  
Apr-06-21 04:30PM  
Mar-31-21 01:33PM  
Mar-30-21 10:06AM  
Mar-29-21 02:34PM  
12:04PM  
Mar-24-21 03:43PM  
Mar-23-21 05:13AM  
Mar-19-21 09:40AM  
08:13AM  
07:46AM  
07:12AM  
Mar-18-21 04:30PM  
Mar-17-21 11:48AM  
Mar-11-21 09:37AM  
08:00AM  
Mar-04-21 02:47PM  
Mar-03-21 09:43AM  
06:45AM  
Feb-26-21 03:00AM  
Feb-22-21 09:18AM  
08:00AM  
Feb-19-21 08:00AM  
Feb-11-21 09:13AM  
08:00AM  
03:06AM  
Feb-10-21 11:57AM  
10:05AM  
Feb-09-21 02:00PM  
01:30PM  
08:45AM  
07:13AM  
07:00AM  
06:15AM  
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor for the treatment of adults; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug that is in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase III clinical trial to treat naive chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; and Cellenkos, Inc., as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wenqing YaoEVP, Head of Discovery ChemJun 29Sale85.3727,1942,321,55294,080Jun 30 04:11 PM
Pasquale Maria EEVP & General CounselJun 18Option Exercise65.3625516,66730,193Jun 22 04:04 PM
Dhanak DashyantEVP & Chief Scientific OfficerJun 10Option Exercise65.423,845251,54030,390Jun 14 04:28 PM
Dhanak DashyantEVP & Chief Scientific OfficerJun 10Sale87.003,845334,51526,545Jun 14 04:28 PM
Dhanak DashyantEVP & Chief Scientific OfficerJun 01Sale84.1339533,23126,545Jun 03 04:42 PM
BAKER BROS. ADVISORS LPDirectorMay 14Option Exercise18.9740,000758,80029,334,516May 18 04:25 PM
Pasquale Maria EEVP & General CounselApr 23Option Exercise65.361278,30129,938Apr 27 04:57 PM
Dhanak DashyantEVP & Chief Scientific OfficerApr 01Sale81.5739632,30227,336Apr 05 04:25 PM
Morrissey Michael JamesEVP, Head of Tech. OperationsMar 29Sale81.0820,0001,621,60045,452Mar 31 04:10 PM
Pasquale Maria EEVP & General CounselMar 12Option Exercise65.361288,36630,328Mar 16 04:17 PM
Dhanak DashyantEVP & Chief Scientific OfficerMar 01Sale79.7339531,49327,732Mar 03 04:28 PM
Hoppenot HerveChairman / CEOFeb 23Buy77.3712,9251,000,007284,231Feb 23 04:54 PM
Pasquale Maria EEVP & General CounselFeb 16Option Exercise65.361278,30130,200Feb 18 04:38 PM
Dhanak DashyantEVP & Chief Scientific OfficerFeb 01Option Exercise65.4296162,86929,483Feb 03 04:27 PM
Dhanak DashyantEVP & Chief Scientific OfficerFeb 01Sale90.001,356122,04028,127Feb 03 04:27 PM
Iyengar Vijay KEVP GPS, BD, & LicensingJan 25Option Exercise72.864,116299,89231,274Jan 27 05:03 PM
Wenqing YaoEVP, Head of Discovery ChemJan 25Option Exercise73.2121,5451,577,309163,770Jan 27 05:32 PM
Stein Steven HEVP & Chief Medical OfficerJan 25Option Exercise68.623,795260,413123,539Jan 27 05:09 PM
Wenqing YaoEVP, Head of Discovery ChemJan 25Sale100.0021,5452,154,500143,784Jan 27 05:32 PM
Iyengar Vijay KEVP GPS, BD, & LicensingJan 25Sale99.005,116506,48426,158Jan 27 05:03 PM
Stein Steven HEVP & Chief Medical OfficerJan 25Sale100.003,795379,500119,744Jan 27 05:09 PM
Flannelly Barry PEVP & General Manager USJan 25Sale100.002,744274,40049,994Jan 27 04:52 PM
Pasquale Maria EEVP & General CounselJan 11Option Exercise65.361278,30130,073Jan 13 04:15 PM
Pasquale Maria EEVP & General CounselDec 11Option Exercise65.361288,36629,946Dec 15 04:51 PM
Pasquale Maria EEVP & General CounselNov 12Option Exercise65.361278,30128,586Nov 16 04:56 PM
BIENAIME JEAN JACQUESDirectorNov 10Sale83.0079866,2348,646Nov 12 04:41 PM
Dhanak DashyantEVP & Chief Scientific OfficerNov 06Option Exercise65.4296162,86928,971Nov 10 04:26 PM
Dhanak DashyantEVP & Chief Scientific OfficerNov 06Sale85.1796181,84828,010Nov 10 04:26 PM
Flannelly Barry PEVP & General Manager USNov 02Option Exercise48.4420,000968,80059,984Nov 04 04:15 PM
Flannelly Barry PEVP & General Manager USNov 02Sale86.6020,0001,732,00039,984Nov 04 04:15 PM
Pasquale Maria EEVP & General CounselOct 12Option Exercise65.361288,36628,459Oct 13 05:10 PM
Pasquale Maria EEVP & General CounselOct 09Option Exercise68.621,42397,64629,754Oct 13 05:10 PM
Pasquale Maria EEVP & General CounselOct 09Sale95.001,423135,18528,331Oct 13 05:10 PM
Dhanak DashyantEVP & Chief Scientific OfficerOct 06Option Exercise65.4296162,86928,971Oct 08 04:21 PM
Dhanak DashyantEVP & Chief Scientific OfficerOct 06Sale91.9796188,38328,010Oct 08 04:21 PM
Pasquale Maria EEVP & General CounselSep 11Option Exercise65.361278,30128,331Sep 14 04:19 PM
Pasquale Maria EEVP & General CounselSep 10Option Exercise65.362,193143,33430,397Sep 14 04:19 PM
Pasquale Maria EEVP & General CounselSep 10Sale90.832,193199,19028,204Sep 14 04:19 PM
Dhanak DashyantEVP & Chief Scientific OfficerSep 08Option Exercise65.4296162,86928,971Sep 10 04:21 PM
Dhanak DashyantEVP & Chief Scientific OfficerSep 08Sale88.9496185,47128,010Sep 10 04:21 PM
DIXON WENDY LDirectorAug 27Option Exercise18.9720,000379,40034,243Aug 31 04:26 PM
DIXON WENDY LDirectorAug 27Sale94.5120,0001,890,20014,243Aug 31 04:26 PM
Pasquale Maria EEVP & General CounselAug 10Option Exercise65.361288,36628,204Aug 12 04:08 PM
Dhanak DashyantEVP & Chief Scientific OfficerAug 06Option Exercise65.4296162,86928,971Aug 10 04:20 PM
Dhanak DashyantEVP & Chief Scientific OfficerAug 06Sale97.8096193,98628,010Aug 10 04:20 PM